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The White Whale swam before him as the monomaniac incarnation of all those
malicious agencies which some deep men feel eating in them, till they are left living
on with half a heart and half a lung. That intangible malignity which has been from
the beginning; to whose dominion even the modern Christians ascribe one-half of
the worlds; which the ancient Ophites of the east reverenced in their statue
devil—Ahab did not fall down and worship it like them; but deliriously transferring
its idea to the abhorred white whale, he pitted himself, all mutilated, against it. All
that most maddens and torments; all that stirs up the lees of things; all truth with
malice in it; all that cracks the sinews and cakes the brain; all the subtle
demonisms of life and thought; all evil, to crazy Ahab, were visibly personified, and
made practically assailable in Moby Dick. He piled upon the whale’s white hump
the sum of all the general rage and hate felt by his whole race from Adam down;
and then, as if his chest had been a mortar, he burst his hot heart’s shell upon it.
Herman Melville, Moby Dick
For Agnes and Fred
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ABSTRACT
Cell division lies at the foundation of the biology of all organisms. Single cell
organisms employ cell division as a means to propagate while multi-cellular
organisms require an enormous amount of cellular proliferation during embryonic
development in order to establish the body plan and expand cell numbers for organ
and tissue building. Cell proliferation is equally important in the adult organism as it
is required to maintain organ and tissue homeostasis by replacing cells that are
either lost or die.
The basic scheme of cell proliferation is rooted in a multi-step process whereby an
external mitogenic growth signal acts upon a quiescent cell to invoke a cascade of
molecular events resulting in a proliferative state. Mitogenic signals are received by
binding to transmembrane receptors which then transmit signals through the
cytoplasm utilizing a wide variety of signal transduction molecules. Growth signals
ultimately converge in the nucleus where a subset of molecules that coordinate cell
division are activated. In this study my colleagues and I have experimentally
addressed the function of two distinct regulators of the cell proliferation: Mat1 and
Lkb1.
Cell cycle progression is mediated in part by the coordinated activity of cyclin-
dependent kinases (Cdks). Cdks are themselves regulated by several mechanisms
including an activating phosphorylation that is required for full Cdk activity. The
enzymes that catalyze this activation are known as Cdk-activating kinases or
CAKs. In mammals, CAK activity appears to be a function of a trimeric complex
comprised of Cdk7, cyclin H and Mat1. Intriguingly, the Cdk7-cyclin H-Mat1 trimer
also provides the kinase activity of the 9-subunit basal transcription factor TFIIH,
where it is involved in the phosphorylation of the C-terminal domain (CTD) of the
large subunit of RNA polymerase II (pol II).
In order to address the role of Mat1 in vivo, we have generated several targeted
alleles of Mat1 by homologous recombination in ES cells. We report that Mat1 is
required for murine embryonic development as disruption of Mat1 leads to peri-
implantation lethality. In culture, early Mat1-/- embryos gave rise to viable post-
mitotic trophoblast giant cells while mitotic lineages failed to proliferate and survive.
In contrast to wild-type trophoblast giant cells, Mat1-/- cells were defective in
endoreduplication and became arrested in the endocycle. Additionally, Mat1-/- cells
exhibited defects in phosphorylation of the C-terminal domain (CTD) of RNA
polymerase II. These results provide evidence for the requirement of murine Mat1
both in cell cycle progression and in modulating CTD phosphorylation.
To further characterize Mat1 in adult mitotic and post-mitotic lineages, a Cre/loxP
strategy was utilized to conditionally target Mat1 in the adult germline and in
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myelinated Schwann cells. This was achieved by crossing conditional Mat1
animals to mice expressing the Cre recombinase under the control of the
endogenous Krox-20 promoter. We found that, much like embryonic mitotic
lineages, the germ cell lineage was rapidly rendered non-viable upon disruption of
Mat1 resulting in reproductive infertility of the targeted animals. Post-mitotic
Schwann cells on the other hand were fully able to complete the normal process of
myelination in the absence of Mat1. However, with time, the post-mitotic Schwann
cells also succumbed to Mat1 disruption resulting in a progressive neuromuscular
atrophy in the targeted animals. Interestingly, analysis of this phenotype suggested
that non-myelinated Schwann cells are capable of remyelinating demyelinated
axons in this system.
Evidence that the serine-threonine kinase LKB1 is involved in regulating some
aspect of cell proliferation has its origin in the identification of LKB1 as a tumor
suppressor gene mutated in Peutz-Jeghers syndrome (PJS). PJS is a rare
inherited disease in which patients develop gastrointestinal hamartomatous polyps
in early adulthood, exhibit mucocutaneous pigmentation on the skin and oral
mucosa, and have an increased risk of developing cancers in later life. Inactivating
mutations of LKB1 underlie the majority of Peutz-Jeghers families although the
mechanisms by which LKB1 mutation predisposes to tumor formation and cancer
development are unknown.
We have attempted to address the function of murine Lkb1 in vivo by genetically
engineering mice with targeted Lkb1 alleles. We found that homozygous disruption
of Lkb1 led to embryonic lethality at mid-gestation indicating that Lkb1 is essential
for murine development. Closer examination of embryonic development revealed
that Lkb1-/- conceptuses exhibit severe defects in both embryonic and extra-
embryonic vasculature which was coupled with a tissue specific-deregulation of
VEGF. Moreover, when Lkb1-/- cells were cultured, they exhibited increased
expression of VEGF suggesting that loss of Lkb1 may confer an increased
angiogenic potential on some cell types. This finding could therefore provide a
rationale to explain why loss of LKB1 in human PJS patients predisposes to tumor
development and cancer.
As Lkb1 heterozygous animals represent the genetic equivalent of human PJS
patients with germline LKB1 mutations, we therefore wanted to determine if Lkb1+/-
animals exhibited any of the phenotypes characteristic of PJS. As they aged, we
observed that these mice develop gastrointestinal polyps that were histologically
indistinguishable from polyps resected from PJS patients. These results establish
that murine Lkb1 functions as a tumor suppressor and that Lkb1+/- mice model
human PJS polyposis. Surprisingly, we found that biallelic inactivation of Lkb1 was
not associated with polyp formation indicating that Lkb1 can be haploinsufficient for
tumor suppression. Analysis of the molecular mechanisms underlying Lkb1+/-
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polyposis revealed that cyclooxygenase-2 (COX-2) was highly upregulated in
murine polyps. Subsequent examination of a large series of human PJS polyps
revealed that COX-2 was also highly upregulated in the majority of these polyps
suggesting that COX-2 inhibitors could be used to lower the tumor burden in PJS
patients.
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REVIEW OF THE LITERATURE
1 The Cell Cycle
Most somatic cells that are actively cycling pass through four distinct phases of the
cell cycle. During the G1 phase, protein and RNAs are synthesized and the cell
monitors its environment, and its own size for signals for progression. S phase
marks the period of the cell cycle in which the DNA comprising the genome is
replicated. G2 denotes the phase of the cycle between S phase and mitosis in
which the cell ensures that the DNA has been properly replicated and readies for
division. M phase demarcates the mitotic phase of the cell cycle whereby the
replicated chromosomes are segregated into separate nuclei followed by cell
division.
Although the details vary depending on cell type, the cell cycle is comprised of the
set of processes needed to produce a pair of genetically identical daughter cells.
To do this, the cell must first faithfully replicate its genome, and, for the vast
majority of cells, double its mass and duplicate all of its cytoplasmic organelles
before division. In certain types of specialized cells however, DNA synthesis occurs
by a process known as endoreduplication whereby successive rounds of G and S
phases proceed without intervening mitosis (Barlow et al., 1972). As a
consequence, endocycling cells acquire vast quantities of DNA in their nuclei
thereby becoming polyploid (Varmuza et l., 1988). Passage through both the
mitotic cell cycle and the endocycle relies on the coordinated activity of a large
number of molecules to ensure fidelity. When the mechanisms that govern the cell
cycle become deregulated, the consequences on the cell may be manifested in cell
death, uncontrolled growth or aberrant differentiation.
1.1 Cdks are Mediators of the Cell Cycle
Progression through the cell cycle is mediated by the sequential activation of
cyclin-dependent kinases (Cdks) (Figure 1). Cdks function by phosphorylating
cellular targets which in turn coordinate passage through the cell cycle. First
identified by genetic analysis of the yeast cell cycle, and in studies on frog and
marine invertebrate embryos, Cdks have since been recognized to lie at the heart
of the cell cycle in all eukaryotic organisms (Nurse, 1990; Hunt, 1991; Norbury and
Nurse, 1992).
Cdks are heterodimeric protein complexes comprised of a catalytic kinase domain
and a regulatory cyclin subunit. The kinase subunit of Cdks conforms to the basic
protein kinase structural motif consisting of a b-sheet-rich amino terminal lobe and
an a-helix-rich carboxy terminal lobe with the catalytic kinase domain lying between
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the two (Pavletich, 1999). To date, at least nine different Cdks have been identified
in mammalian cells (Cdk1-9). The cyclin subunits of Cdks are required for Cdk
catalytic activity and appear to play a role in dictating the specificity of Cdk activity
(Roberts, 1999). At least 16 different cyclins have been identified in mammalian
cells (Johnson and Walker, 1999).
Figure 1. Cdk Activity Through the Mammalian Cell Cycle
The kinase activity of the indicated Cdk/cyclin pairs throughout the different phases of the cell cycle
is approximated by the width of the graded bands. Adapted from (Lodish, 2000).
1.2 Cellular Targets of Cdks
Despite their central role in cell cycle progression surprisingly little is known about
how the activity of Cdks modulate the function of their biological targets. Two
notable exceptions are the retinoblastoma susceptibility protein family (RB), and
the nuclear protein mapped to the ATlocus (NPAT).
Rb is a nuclear phosphoprotein that functions to arrest cells in the G1 phase of the
cell cycle (Weinberg, 1995; Harbour and Dean, 2000). One of the ways that Rb
exerts this suppressive effect is by binding to and sequestering E2F transcription
factors thereby rendering them unable to transactivate genes critical for cell cycle
progression (Dyson, 1998). In its hypophosphorylated form, Rb has a high affinity
for E2F transcription factors that it binds to through a central ‘pocket’ domain. Upon
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phosphorylation by Cdk complexes Rb looses its affinity for E2F thereby liberating
a free pool of E2F which is then able to transactivate target gene promoters and
advance the cell cycle. Interestingly, inactivation of Rb by Cdks appears to be a
sequential process as evidence shows that Rb is first phosphorylated by Cdk4-
cyclin D and Cdk6-cyclin D, and subsequently by Cdk2-cyclin E thereby regulating
Rb activity in a coordinated, step-wise fashion (Lundberg and Weinberg, 1998;
Harbour et al., 1999; Zhang et al., 2000).
As histone proteins constitute nearly half of the mass the chromatin, histone
biosynthesis during S phase is critical for the advancement of the cell cycle (Ewen,
2000). Originally identified as an interacting protein of Cdk2-cyclin E by a protein
interaction screen, NPAT was demonstrated to be phosphorylated by Cdk2-
cyclin E and to accelerate the progression from G1 to S phase when ectopically
expressed (Zhao et al., 1998). These findings suggested that the interaction of
NPAT with Cdk2-cyclin E had relevance for cell cycle progression. Subsequent
studies demonstrated that the phosphorylation of NPAT by Cdk2-cyclin E is
involved in NPAT’s ability to positively regulate the transcription of histones H2B,
H4 and H3 in a S phase dependent manner (Ma et l., 2000; Zhao et al., 2000).
These reports have thereby provided evidence on how the activity of Cdk2-cyclin E
coordinates one of the larger scale periodic cell cycle industries that take place in
mammalian cells: that of histone synthesis.
1.3 Cdk Regulation
Due to their central role in coordinating cell cycle progression, Cdks themselves
are subject to many levels of regulation in response to both intracellular and
extracellular signals. Since Cdks are catalytically inactive in the absence of their
requisite positive regulatory cyclin subunit, the first level of Cdk regulation is cyclin
availability. Most cyclins are unstable and undergo periodic synthesis and
destruction thereby providing the preeminent mechanism by which Cdk activity is
regulated (Ekholm and Reed, 2000). Structural analysis has revealed that cyclins
positively regulate Cdk activity upon binding by inducing a conformational change
in the Cdk that allows substrate binding and catalysis (Jeffrey et al., 1995).
A further level of Cdk regulation is provided by the action of Cdk-inhibitory
molecules (CKIs). Two families of CKIs have been identified in mammalian cells:
the INK4 proteins (inhibitors of Cdk4), which include p16INK4A, p15INK4B p18INK4C, and
p19INK4D, and the Cip/Kip family, which include p21CIP1, p27KIP1 and p57KIP2. The
INK4 family of inhibitors bind directly to Cdk4 and Cdk6 while the Cip/Kip family of
inhibitors bind to Cdk-cyclin heterodimers (Sherr and Roberts, 1995). The
regulation of cell cycle progression by CKIs took on a new level of complexity with
the discovery that while Cip/Kip proteins inhibit the activity of Cdk2-cyclin E and
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Cdk2-cyclin A complexes, they also act as positive regulators of Cdk4/6-cyclin D
complexes (Sherr and Roberts, 1999).
Cdks are also tightly regulated at the level of post-translational modification. When
in complex with their cognate cyclin, Cdks are rendered sensitive to
phosphorylation on two adjacent residues (Tyr15 and Thr14) whose phospho-forms
inhibit Cdk activity by inducing conformational changes in the catalytic domain
(Morgan, 1997). These inhibitory phosphorylations are in turn removed by the
Cdc25 family of dual-specificity phosphatases (Nilsson and Hoffmann, 2000).
In addition to cyclin binding, most Cdks require phosphorylation on a conserved
residue to become fully active. This phosphorylation, which was first described in
yeast (Gould et al., 1991), modifies a conserved threonine in the T-loop to induce a
conformational change that facilitates substrate binding (Russo et al., 1996). The
kinases that catalyze this phosphorylation are known as Cdk-activating kinases
(CAKs).
1.4 Cdk activating kinases (CAKs)
The first biochemical purification of a CAK activity was achieved in fractionation
experiments in which an isolated kinase activity was shown to be capable of
phosphorylating and activating Cdk1 (Solomon et al., 1992). Subsequent
identification of the proteins comprising this CAK activity revealed a trimeric
complex comprised of Cdk7, cyclin H and Mat1 (Solomon et al., 1993; Tassan et
al., 1994). In vitro, the mammalian Cdk7-cyclin H-Mat1 trimer has been shown to
phosphorylate and activate Cdk1, Cdk2, Cdk3, Cdk4, and Cdk6 when in complex
with their cognate cyclin partners (Kaldis, 1999).
Perhaps contrary to expectations, the CAK activity in the budding yeast
Saccharomyces cerevisiae was found to be provided by a monomeric kinase
named Cak1/Civ1 with surprisingly little homology to mammalian CAK (Espinoza et
al., 1996; Kaldis et al., 1996; Thuret et al., 1996). This finding fueled a debate
wherein it was suggested that a similar single subunit CAK might also be active in
mammalian cells and that the CAK activity provided by Cdk7-cyclin H-Mat1 might
actually represent in vitro artifact. The CAK debate was further complicated when it
was discovered that in the fission yeast Schizosaccharomyces pombe, both the
Cdk7 related Mcs6 kinase complex as well as a single subunit kinase Csk1
possessed CAK activity in vivo (Hermand et al., 1998; Lee et al., 1999; Hermand et
al., 2001). To date, the best evidence that Cdk7-cyclin H-Mat1 functions as a CAK
in metazoan species comes from experiments with the Drosophila Cdk7 homolog
which demonstrated that Cdk7 kinase activity was required for the proper activation
of mitotic Cdk-cyclins in vivo (Larochelle et al., 1998).
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2 At the Crossroads of the Cell Cycle, DNA Repair and
Transcription
Shortly after their identification as Cdk activators, Cdk7-cyclin H-Mat1 - along with
the homologous Kin28-Ccl1-Tfb3 complex of S. cerevisiae - were identified to be
components of the basal transcription factor TFIIH (Feaver t al., 1994; Serizawa
et al., 1995; Shiekhattar et al., 1995). This finding was intriguing in its suggestion
that one kinase activity might be involved in mediating three critical cellular
processes; cell cycle progression, basal transcription and transcription coupled
nucleotide excision repair (NER). At the same time however, these discoveries
added fuel to the debate surrounding the physiological role of Cdk7-cyclin H-Mat1,
as it became apparent that the actual in vivo capacities of homologous kinases
from different species exist. Notably, the Kin28-Ccl1-Tfb3 complex of S. cerevisiae
was shown to function only in TFIIH-mediated transcription and not in Cdk
activation (Cismowski et al., 1995; Valay et al., 1995).
2.1 Transcription factor IIH (TFIIH)
The basal transcription factor TFIIH is known to function in RNA polymerase II
(pol II) mediated transcription where, in concert with at least five other basal
transcription factors (TFIIB, TFIID, TFIIE and TFIIF), it is critically involved in
transcription initiation (Roeder, 1996). During transcription initiation TFIIH has been
shown to catalyze the ATP-dependent formation of the open complex as well as
being involved in efficient promoter escape by suppression of early pol II elongation
intermediates (Dvir et al., 2001). TFIIH is also known to function in transcription-
coupled nucleotide excision repair (Citterio et al., 2000).
Structure/function studies have indicated that TFIIH can be resolved into several
functional subcomplexes; a core TFIIH complex comprised of five subunits (p44,
p52, p62, p34 and XPB), and the kinase complex of Cdk7, cyclin H and Mat1 (Egly,
2001). The remaining XPD subunit can be found associated with either the
core TFIIH or with the kinase subunit and seems to be the means by which the
kinase subunit associates with the core to form the nine subunit TFIIH holoenzyme
(Busso et al., 2000).
Recently, 3-dimensional models of mammalian and yeast TFIIH have been
determined with the use of electron microscopy images of purified TFIIH
subcomplexes (Chang and Kornberg, 2000; Schultz et al., 2000). These models
suggest that the core subunits of TFIIH form a ring-like structure, which encircle a
central cavity large enough to accommodate a double stranded DNA molecule. The
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kinase subunit appears to contact the ring structure on one discreet surface to form
a protruding bulge (Schultz e  al., 2000).
In addition to the kinase activity provided by Cdk7-cyclin H-Mat1, TFIIH also
contains two additional catalytic subunits, XPD and XPB, both of which are ATP-
dependent DNA helicases. Of these, XPB appears to have a critical role both in
promoter melting at transcription initiation, and in DNA repair (Egly, 2001).
Mutations disabling XPB helicase activity abolish both of these functions (Tirode et
al., 1999). XPD on the other hand seems to be less critical for promoter clearance
as demonstrated by systems in which mutations that disrupt XPD helicase activity
are still capable of in vitro transcription albeit at sub-optimal levels (Tirode et al.,
1999).
The role of TFIIH kinase in NER is still in debate with some studies suggesting that
kinase activity negatively regulates NER (Araujo et al., 2000) while others have
suggested that TFIIH kinase activity plays no role in this aspect of TFIIH function
(Svejstrup et al., 1995). The importance of both TFIIH helicases in NER however is
underscored by the fact that mutations in XPD or XPB can lead to the human DNA
repair deficiency syndromes Xeroderma pigmentosum, Cockayne syndrome and
trichothiodystrophy (Egly, 2001; Lehmann, 2001).
2.2 Substrates of TFIIH kinase
The most extensively studied substrate of TFIIH kinase activity is the heptapeptide
repeat sequence (consensus YSPTSPS) which comprises the C-terminal domain
(CTD) of the large subunit of RNA polymerase II (Rpb1). In vitro, TFIIH kinase
activity is primarily directed at serine 5 (Ser-5) of the heptapeptide repeat (Gebara
et al., 1997; Sun et al., 1998; Trigon et al., 1998), although there is some evidence
that serine at position 2 (Ser-2) might also be phosphorylated (Watanabe et al.,
2000).
Accumulating evidence suggests that the primary role of CTD phosphorylation
during pol II-mediated transcription is in the recruitment of proteins necessary for
proper processing of the nascent transcript. Numerous transcript maturation
proteins such as polyadenylation factors (McCracken et al., 1997b), mRNA capping
factors (McCracken et al., 1997a) and splicing factors (Misteli and Spector, 1999)
have all been shown to associate with phosphorylated forms of the CTD.
Numerous other proteins have emerged which have the potential of being
physiologically relevant substrates of TFIIH kinase activity. These include p53 (Ko
et al., 1997), the POU domains of the Oct factors (Inamoto et al., 1997), retinoic
acid receptor alpha (Rochette-Egly et al., 1997), and estrogen receptor alpha
(Chen et al., 2000). It seems likely however that phosphorylation of at least some
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of these proteins may be catalyzed by the Cdk7-cyclin H-Mat1 trimer outside of the
context of TFIIH.
2.3 Ménage à trois (Mat1)
The initial observations that Mat1 co-purified with Cdk7 and cyclin H in
stoichiometric amounts marked the first example of a third protein partner positively
impinging upon the sanctity of the Cdk-cyclin binary complex (Devault et al., 1995;
Fisher et al., 1995; Tassan et al., 1995). However, the roles of Mat1 in the trimeric
Cdk7-cyclin H-Mat1 kinase, and as a subunit of TFIIH are only beginning to be
understood.
Originally, Mat1 was shown to enhance cyclin H and Cdk7 complex formation in
the absence of Cdk7 T-loop phosphorylation and was therefore suggested to act as
an assembly factor for the CAK kinase (Devault et al., 1995; Fisher et al., 1995;
Tassan et al., 1995). A higher order function for Mat1 in protein complex assembly
was revealed by structure/function studies which suggests that Mat1 physically
mediates the interaction between Cdk7-cyclin H-Mat1 and core TFIIH through
contact with the XPD helicase (Busso et al., 2000; Sandrock and Egly, 2001).
Several studies have suggested a role for Mat1 in the control of substrate
specificity whereby Mat1 shifts the kinase activity of dimeric Cdk7-cyclin H from
Cdk substrates towards CTD substrates (Inamoto et al., 1997; Rossignol et al.,
1997; Yankulov and Bentley, 1997). These observations are consistent with a
fundamental role for Mat1 in linking the Cdk7-cyclin H-Mat1 trimer to core TFIIH.
The primary amino acid sequence of Mat1 reveals the presence of two conserved
structural domains: a canonical RING finger domain and a coiled-coil domain.
Structure/function studies have suggested that the N-terminally located RING
finger domain of Mat1 is crucial for transcriptional activation and is involved in CTD
phosphorylation (Busso et al., 2000). The central coiled-coil domain appears to
mediate the contact of Mat1 with TFIIH through interaction with XPD (Busso et al.,
2000). The C-terminal sequences Mat1 appear to be sufficient to mediate the
assembly of Cdk7-cyclin H-Mat1 trimers (Tassan et l., 1995; Busso et al., 2000).
3 Cancer and Inherited Cancer Susceptibility Syndromes
During the last century, cancer has emerged as one of the leading causes of
mortality worldwide. In particular, a dramatic rise in cancer incidence has been
observed in developed nations (Doll, 1978). This is almost certainly due in part to
the fact that as health care improves, so too do people live longer and thus the
likelihood of developing cancer over a lifetime is increased. Indeed, a striking link
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between advanced age and increased incidence of cancer has clearly emerged
(Piantanelli, 1988) (Figure 2). It has been proposed that cancer incidence may
increase with age as a result of the combined effects of mutation load, epigenetic
regulation, telomere dysfunction and altered stromal milieu (DePinho, 2000).
Figure 2. Cancer incidence as a function of age.
Incidence of invasive cancer plotted against age ranges of men and women. Adapted from
(Piantanelli, 1988).
Although aging is clearly an important determinant of cancer risk, epidemiological
studies have shown that a wide variety of external factors such as smoking, diet,
and infectious pathogens, along with a myriad of factors attributable to the
workplace and the environment, can also result in an increased cancer risk (Peto,
2001). No one example better illustrates this point more succinctly than the
dramatically elevated risk of developing lung carcinoma that accompanies long
term cigarette smoking (Doll and Hill, 1950; Wynder and Graham, 1950). It is now
known that many of the agents that elevate cancer risk contain components that
incur DNA damage and result in genetic lesions (Loechler, 1996). Such mutations
contribute to cancer development by a variety of mechanisms such as disabling the
regular growth control of the cell (loss-of-function mutations), or by selectively
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facilitating the growth of cancerous cells or their precursors (gain-of-function
mutations).
Well before the actual molecular mechanisms had been revealed, clinical
observation and histopathological analysis had shown that cancer develops
through a multi-step process (Figure 3) (Foulds, 1954; Stenback, 1980). A great
deal of experimental evidence from human and animal systems has subsequently
demonstrated that the process by which normal cells develop into malignant
cancerous cells involves the successive acquisition of genetic alterations
(Vogelstein et al., 1988; Vogelstein and Kinzler, 1993).
Although there are over 100 distinct types of cancer and subtypes of tumors
described in humans, it has been proposed that most (and perhaps all) result from
alterations in six essential aspects of cell physiology: self-sufficiency in growth
signals, insensitivity to growth inhibitory signals, evasion of apoptosis, limitless
replicative potential, sustained angiogenesis, and tissue invasion and metastasis
(Hanahan and Weinberg, 2000). As each of these capabilities is acquired, a key
physiological barrier to cancer development is breached, and the cell is furthered in
its progression to malignancy. A vast body of literature characterizing the precise
genetic alterations underlying the development of many cancer types has emerged
with the bulk of the culpability falling onto two categories of genetic lesion: those
that activate oncogenes, and those that inactivate tumor suppressor genes.
Figure 3. Multi-Step Progression to Cancer.
Histopathological changes observed in tissues progressing from a normal to a metastatic cancer
state. Adapted from (Vogelstein and Kinzler, 1993).
3.1 Oncogenes
Originally identified in retroviruses, oncogenes were first shown to have the
capacity to induce malignant transformation in cultured cells (Bishop et al., 1973;
Varmus et al., 1973). Subsequently, homologous counterparts of retroviral
oncogenes were discovered to be normally encoded in the genomes of higher
organisms (Stehelin et al., 1976; Hampe t al., 1982). These cellular genes, termed
proto-oncogenes, are now known to play wide ranging roles in cell signaling,
growth control and differentiation (Blume-Jensen and Hunter, 2001). Mutations that
alter the normal cellular properties of proto-oncogenes underlie the oncogenic
potential that these genes exhibit in cancer development (Parada et al., 1982;
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Tabin et al., 1982; Varmus, 1984). Oncogenic mutations can be manifested in a
variety of ways such as overexpression, gene amplification, fusion proteins
resulting from chromosomal translocations, and gain-of-function point mutations
(Bishop, 1991).
Of the signaling cascades susceptible to oncogenic transformation, none is as
widely studied as those that emanate from the Ras proto-oncogene. Ras is a small
(21 kD) membrane bound monomeric G protein that activates numerous signaling
pathways through a variety of different effector molecules such as PI 3-kinase and
Raf (McCormick, 1999). Mutations that affect the conformation of Ras to favor its
active (GTP bound) form lie at the foundation of the oncogenic potential of Ras.
Such oncogenic Ras variants are thereby uncoupled from upstream regulators, and
are thus able to constitutively manufacture mitogenic and survival signals for the
cell (Ayllon and Rebollo, 2000). By doing so, oncogenic Ras provides a degree of
self-sufficiency in terms of mitogenic signals while at the same time contributing to
the ability of the cell to evade apoptosis. The frequency of oncogenic Ras
mutations has been found to be very high in human cancer development with
approximately 25% of all human cancers and up to 50% of human colon
carcinomas exhibiting Ras mutations (Vogelstein et al., 1988). These numbers are
a testament of the magnitude of the growth/survival advantage that oncogenic Ras
imparts onto malignant cells.
3.2 Tumor Suppressors: Caretakers, Gatekeepers and Landscapers
Although the vast majority of cancers develop sporadically without a familial basis,
a small percentage of cancers, estimated to represent up to 10% of cases, are
attributable to inherited components (Ponder, 2001). Familial cancers fall into two
general categories. The first of these are ascribed to multiple genetic loci, and
predispose to cancer under the influence of combinations of alleles from numerous
loci. These so called, multi-factorial familial cancers do not display Mendelian
inheritance and the likelihood of individuals at risk of developing cancer is usually
weak to moderate. The second class of familial cancers, which account for only 1-
2% of all cancers, are usually attributable to a single predisposing locus. These
malignancies, known as inherited cancer syndromes, are inherited in dominant
Mendelian fashion and are often associated with developmental defects and non-
neoplastic phenotypes such as benign tumor formation. The relative risk of
developing malignant cancers in inherited cancer syndromes is often very high with
lifetime risk assessments of up to 80% for some of these syndromes (Ponder,
2001). Inherited cancer syndromes are associated with mutation of a class of
genes known as tumor suppressors. Although inherited cancer syndromes are
quite rare, the tumor suppressors underlying these syndromes are frequently found
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to be somatically mutated in sporadic cancers pointing to the vital role these
molecules normally play in growth control and differentiation. Tumor suppressors
have been classified into three groups: gatekeepers, caretakers, and landscapers
(Kinzler and Vogelstein, 1997; Kinzler and Vogelstein, 1998).
The term ‘gatekeeper’ has been given to genes whose encoded products directly
regulate the growth of tumors through inhibition of cellular proliferation and
promotion of cell death. Inactivation of these genes is rate-limiting for tumor
development and it has been suggested that both the maternal and paternal copies
of the gatekeeper must be inactivated in order to promote tumorigenesis (Knudson,
1996). It has been proposed that different cell types employ only one (or a few)
gatekeepers as the central cellular ‘brake’ thereby providing a rationale for the
specificity of varied tumor types observed in patients (Kinzler and Vogelstein,
1997). Thus inactivation of Rb, VHL, NF1, or APC leads to tumors of the retina
(Lee et al., 1987), kidney (Latif et al., 1993), Schwann cells (Cawthon et al., 1990;
Viskochil et al., 1990; Wallace t al., 1990) and colon (Kinzler t al., 1991; Nishisho
et al., 1991) respectively.
A second category of tumor suppressor genes is the so-called ‘caretakers’ whose
encoded products are involved in mediating DNA repair. Caretaker subgroups
include proteins involved in; mismatch repair e.g. MSH2/3/6 and MLH1 (Kolodner
and Marsischky, 1999), nucleotide excision repair e.g. XPD and XPB (Hoeijmakers,
2001; Svejstrup, 2002), and double-strand break repair e.g. ATM and BRCA1/2
(Khanna and Jackson, 2001). In contrast to gatekeepers whose inactivation directly
promotes tumorigenesis, inactivation of caretaker genes indirectly promotes
neoplasia by rendering the genome unstable. As a consequence, the mutation rate
of all genes is increased including those whose products are involved in tumor
progression (such as gatekeepers and oncogenes). Caretaker inactivation
therefore increases the probability, and accelerates the rate, of neoplastic
transformation.
The third class of tumor suppressor genes, termed ‘landscapers’, are perhaps the
least well characterized due to the fact that the underlying genetic defect does not
reside in the neoplastic cell population itself but rather in the supporting stromal cell
population (Kinzler and Vogelstein, 1998). Mutations in landscaper genes lead to
changes in the tumor microenvironment that facilitate the induction, selection and
expansion of neoplastic populations (Liotta and Kohn, 2001). Indeed, accumulating
evidence suggests that stromal cells can transform adjacent tissues in the absence
of pre-existing tumor cells by inciting phenotypic and genomic changes in adjacent
pre-neoplastic epithelial cells (Tlsty and Hein, 2001).
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4 Peutz-Jeghers syndrome
The first clinical description of Peutz-Jeghers syndrome (PJS) was published in
1921 by J.L.A. Peutz (Peutz, 1921), and was followed some 18 years later with the
publication of an article by H. Jeghers (Jeghers et al., 1949). The defining feature
of PJS is a combination of gastrointestinal hamartomatous polyposis coupled with
abnormal melanin pigmentation on the skin and mucous membranes (Figure 4).
PJS segregates in autosomal dominant fashion with an estimated incidence of
between 1:8300 to 1:29000 live births (Mallory and Stough, 1987). The Mendelian
segregation of clinical features in PJS families suggests a complete penetrance for
PJS (Amos et al., 1997; Hemminki et al., 1997).
The melanin ‘spots’ that are the external hallmark of PJS patients, usually appear
in infancy, reach a maximum at puberty, and tend to fade with age. Persistence of
the pigmentation on the buccal mucosa, however, is common (Jeghers et al.,
1949). The lips and oral mucosa are the most common locations for the spots (94%
of cases), although they are also frequently found on the hands (74% of cases) and
feet (62% of cases) of PJS patients (Utsunomiya et al., 1975). Histologically, the
PJS melanin spots display a basal layer hyperpigmentation that is associated with
an increased number of melanocytes (Stratakis et al., 1998). This histological
feature distinguishes PJS melanin spots from common freckles, which are
pigmented as a result of melanin donation to adjacent keratinocytes.
PJS is typically diagnosed in early adolescence usually as a result of clinical
complications that arise from the polyposis which include bleeding (81% of cases),
and intussusception and obstruction (86% of cases) (Vasen, 2000). Polyps develop
along the full length of the GI tract in PJS patients with the highest frequency found
in the small intestine (Utsunomiya et l., 1975; Burdick and Prior, 1982; Foley et
al., 1988). As a consequence, a large proportion of PJS patients undergo
numerous repeat laparotomies to remove symptomatic polyps (Figure 4) (Vasen,
2000). Histologically, the vast majority of PJS polyps are hamartomatous in
appearance although mixed histologies with adenomatous and hyperplastic
components are not uncommon (Hemminki, 1999). The classic hamartomatous
PJS polyp is pedunculated and frequently cystic, and is comprised of well-
differentiated epithelia with an underlying stromal core of connective tissue. The
stroma typically contains an abundant smooth muscle component, tracks of which
radiate from a central stalk that is contiguous with the muscularis mucosa. The
histology of the smooth muscle component is very characteristic of PJS and is
frequently used in diagnosis to distinguish PJS from other polyposis syndromes
such as juvenile polyposis (Hemminki, 1999).
Prior to 1963, no gastrointestinal cancers had been reported to be associated with
PJS leading to the belief that PJS hamartomas were benign and had little or no
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malignant potential. This notion however was rescinded when histological
examination of biopsied polyps revealed regions of both dysplasia and carcinoma
in situ (Tomlinson and Houlston, 1997). Mounting evidence now suggests that PJS
polyps possess malignant potential which is realized through a hamartoma-
adenoma-carcinoma sequence (Burdick and Prior, 1982; Perzin and Bridge, 1982;
Foley et al., 1988; Spigelman et al., 1989; Hizawa et al., 1993; De Facq et al.,
1995; Defago et al., 1996; Hemminki et al., 1997; Gruber et al., 1998; Wang et al.,
1999b).
Figure 4: Characteristic features of Peutz-Jeghers syndrome.
Typical melanin pigmented macules on the lips and around the mouth of a Peutz-Jeghers patient
(left panel). A pedunculated hamartomatous polyp being surgically removed from a Peutz-Jeghers
patient (right panel).
4.1 Increased cancer risk in PJS
Although early studies had failed to demonstrate an increased cancer risk in PJS
patients (Dormandy, 1957; Burdick, 1963), systematic longer term follow up of
larger patient groups began to yield evidence to the contrary (Dozois et al., 1969;
Dodds et al., 1972; Utsunomiya et al., 1975). Conclusive evidence that PJS was a
cancer predisposition syndrome came in 1987 with the publication of a report
detailing a 12-year follow-up study of 31 PJS patients in which cancer developed in
15 of the patients (48%) (Giardiello t al., 1987). These numbers corresponded to a
relative cancer risk assessment in these PJS patients 18 fold greater than the
general population. Interestingly, of the 15 cancers described, 11 of these were of
extraintestinal origin indicating that the increased cancer susceptibility was not
restricted to the hamartoma-adenoma-carcinoma sequence proposed to
accompany the polyposis.
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Subsequent studies have confirmed the initial findings of Giardiello et al. although
the relative cancer risk assessment of different cancer types has varied
considerably between the different studies (Foley et al., 1988; Spigelman et al.,
1989; Boardman et al., 1998; Westerman et al., 1999). In an attempt to try to
ensure that the variability in risk assessments reported in the literature would not
hamper patient management, a meta-analysis was done in which the findings from
6 separate studies were collated and assessed (Giardiello et al., 2000). This study,
which included data from 210 PJS patients, reported an overall cancer risk 15.2
fold greater than the general population and a 93% cumulative risk of developing
cancer between the ages of 15 and 64. The relative risk of developing specific
types of cancer varied greatly with cancer of the small intestine, stomach and
pancreas being the highest (Table 1).
Site Observed
Cases
Relative Risk
(Observed/Expected)
Cumulative
Risk
(Ages 15-64)
Small Intestine 6 520.0 13.0%
Stomach 10 213.0 29.0%
Colon 15 84.0 39.0%
Esophagus 1 57.0 0.5%
Pancreas 6 132.0 36.0%
Lung 5 17.0 15.0%
Testes 1 4.5 9.0%
Breast 11 15.2 54.0%
Uterus 2 16.0 9.0%
Ovary 4 27.0 21.0%
Cervix 3 1.5 10.0%
All Cancer 66 15.2 93.0%
Table 1: Cancer risk assessment in Peutz-Jeghers syndrome.
Meta-analysis of cancer risk data from 210 Peutz-Jeghers syndrome patients compiled from six
independent studies (adapted from Giardiello et a . 2000).
4.2 Mutations of LKB1 underlie PJS
In 1997, the PJS susceptibility locus was localized to chromosome 19p using a
combination of linkage analysis and comparative genomic hybridization (CGH)
(Hemminki et al., 1997). This localization was subsequently confirmed and refined
to a 6 centimorgan region of 19p13.3 (Amos et al., 1997; Mehenni et al., 1997;
Nakagawa et al., 1998b; Olschwang et al., 1998). Although most PJS families have
mapped to 19p13.3, a smaller subset of families have not suggesting the presence
of additional PJS loci (Mehenni et al., 1997; Olschwang et al., 1998; Olschwang et
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al., 2001). The gene(s) corresponding to the minor PJS loci have yet to be
identified.
Shortly after the localization of the PJS susceptibility locus, two groups
simultaneously reported that germline mutations in a putative serine-threonine
kinase mapping at 19p13.3 underlie PJS (Hemminki et al., 1998; Jenne et al.,
1998). The identified gene, named LKB1, had been previously cloned from a
human fetal liver library and entered into the GenBank database in 1996 (GenBank
accession number U63333) (Nezu, 1996). Despite this, Jenne et al. made an ill-
advised attempt at renaming the gene STK11 – the STK11 name has however
failed to garner wide support in the literature and has instead merely contributed to
a glut of problematic nomenclature.
To date, the vast majority of the germline mutations in PJS families are truncations,
small deletions or point mutations that are predicted to disable LKB1 kinase
function (Gruber et al., 1998; Hemminki et al., 1998; Jenne et al., 1998; Nakagawa
et al., 1998a; Resta et al., 1998; Wang et al., 1999a; Westerman et al., 1999;
Boardman et al., 2000; Yoon et al., 2000; Olschwang et al., 2001).
4.3 Biallelic inactivation of LKB1 in tumorigenesis?
By definition, a recessive tumor suppression gene must undergo biallelic
inactivation to promote tumorigenesis. This two-hit genetic criterion, originally
proposed by Knudson in describing the etiology of retinoblastoma (Knudson,
1971), has adequately described the recessive tumor suppressor function of
numerous genes including Rb (Dryja et l., 1984) and p53 (Baker t al., 1989). The
question about whether LKB1 is a recessive tumor suppressor has been widely
addressed in the literature with inconsistent results. Initially, Hemminki t al.
reported that of 16 polyps that they examined by CGH, only 5 of these presented
evidence for loss of the distal tip of the short arm of chromosome 19 (19p)
(Hemminki et al., 1997). The CGH data was supported in part by PCR amplification
of micro-satellite markers near 19p with loss of heterozygosity (LOH) reported in
3/3 of the polyps screened. These results were interpreted to indicate that the PJS
susceptibility gene did indeed adhere to the criteria of being a recessive tumor
suppressor.
That biallelic inactivation of LKB1 would be rate-limiting for polyp formation has
however been called into question in subsequent studies with some groups
reporting that LOH of micro-satellite markers mapping near LKB1 is frequently
observed in PJS polyps (Gruber t al., 1998; Miyaki et al., 2000), while others have
discovered that LOH of LKB1 may be more rare (Wang et al., 1999b; Entius et al.,
2001). It is likely that these disparate results are attributable to technical difficulties
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arising from contaminating tissues and/or PCR artifact. In an attempt to address
the issue of LKB1 biallelic inactivation using an alternative technique, Rowan et al.
examined expression of LKB1 in a large series of hamartomatous PJS polyps by in
situ hybridization (Rowan et al., 2000). This study reported loss of LKB1 mRNA
expression in only 1 out of 16 polyps examined, thereby casting further doubt on
whether LOH of LKB1 is an obligate initiating event in PJS polyposis. Interestingly,
recent studies have provided evidence suggesting that LOH of LKB1 may be a
more consistent feature of advanced PJS malignancies as opposed to
hamartomatous polyp formation (Su et al., 1999; Entius et al., 2001).
4.4 Evidence for LKB1 Function
A high degree of sequence homology between genes from different species is
often an indicator of a functional homology shared by the encoded proteins. To
date, putative LKB1 homologues have been identified in the frog Xenopus laevis,
the nematode Caenorhabditis elegans, the fruit fly Drosophila melanogaster, and
the mouse Mus musculus. In Xenopus, a protein which shares 84% overall identity
with LKB1, called Xeek1, is highly expressed in the oocyte and fertilized egg but
disappears during gastrulation (Su et al., 1996). Despite the high degree of
sequence identity, the restricted expression pattern of Xeek1 makes it unlikely that
it represents a full functional homologue of LKB1 since the mouse Lkb1 gene
(which encodes a protein with 90% identity to human LKB1) is expressed
ubiquitously throughout murine development (Luukko et al., 1999). The putative
homologue in C. elegans, par-4, shares only 26% identity with LKB1 and is
involved in establishing asymmetries in early embryonic development that are
essential for determining the subsequent developmental fate of daughter cells
(Watts et al., 2000).
The primary sequence of the LKB1 gene predicted that it would encode a protein
with serine-threonine kinase activity (Hemminki et al., 1998; Jenne et al., 1998).
This prediction was validated with the demonstration of an autocatalytic kinase
activity (Ylikorkala et al., 1999). Subsequent work has demonstrated that the
autocatalytic activity is principally directed at two threonine residues, Thr336 and
Thr366 (Sapkota et al., 2002). In addition to its autocatalytic activity, LKB1 has also
been shown to phosphorylate p53 in vitro although whether this phosphorylation is
physiologically relevant is unknown (Sapkota et l., 2001). Interestingly, an
independent group demonstrated that LKB1 physically interacts with p53 and
functions to regulate specific p53-dependent apoptosis pathways (Karuman et al.,
2001). These results suggest that a deficiency in apoptosis may be involved in the
development of PJS polyps and malignancy.
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Though no physiological substrates have yet been identified for LKB1, a recent
paper detailing the interaction of LKB1 with a LIP1 (LKB1-interacting protein 1) has
suggested that LKB1 may have functional links to TGFb  or BMP signaling as LIP1
is able to mediate a LKB1-LIP1-SMAD4 ternary complex (Smith et al., 2001). That
LKB1 may be linked to TGFb  or BMP signaling is particularly intriguing considering
that mutations of both SMAD4 (Howe et al., 1998) and BMPR1A (Howe t al.,
2001) are known to give rise to subsets of patients with juvenile polyposis
syndrome, a disease which is clinically very similar to PJS.
In addition to the cancer predisposition and polyposis phenotypes of PJS patients,
functional evidence that LKB1 is involved in regulating some aspect of cell cycle
progression was provided by Tiainen et al. who showed that reintroduction of LKB1
into tumor cell lines that had reduced LKB1 expression and activity resulted in a G1
cell cycle arrest (Tiainen t al., 1999). An additional piece of evidence that LKB1
controls some aspect of cell cycle regulation comes from a report detailing the
interaction of LKB1 with the cell cycle/chromatin remodeling molecule Brg1,
wherein LKB1 was reported to be required for Brg1-mediated growth arrest in
SW13 cells (Marignani et al., 2001).
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AIMS OF THE STUDY
This study was undertaken to study the function of Mat1 and Lkb1 in vivo. The
approach taken involved the generation and characterization of mice with
genetically engineered mutations in the Mat1 and Lkb1 genes. My collaborators
and I reasoned that such an approach would permit the examination of multiple
aspects of Mat1 and Lkb1 function both during embryonic development, and in the
adult. In this study we have generated and utilized these animals to address the
following:
1. The requirement of Mat1 and Lkb1 during murine embryonic
development.
2. The involvement of Mat1 in the mediation of cell cycle progression and as
a modulator of CTD phosphorylation.
3. The differential requirement of Mat1 in mitotic and post-mitotic lineages.
4. The role of Lkb1 in the development of a murine polyposis syndrome
modeling Peutz-Jeghers syndrome.
5. The molecular biology underlying murine Lkb1-associated polyposis in
order to identify potential targets for therapy for Peutz-Jeghers syndrome
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MATERIALS AND METHODS
A detailed description of the materials and methods are provided in the original
publications.
Generation of Genetically Engineered Mat1 (I, II) and Lkb1 Mice (III, IV)
Genomic sequences spanning the Mat1 and Lkb1 loci were cloned and subjected
to restriction mapping and sequencing. For Mat1, one exon encoding the 3’ half of
the RING finger domain was targeted for ablation utilizing a loxP conditional
targeting strategy (Figure 5). To generate the null allele of Mat1 (Study I), the loxP
conditional target construct was first transformed into a bacterial strain expressing
the Cre recombinase before introduction into ES cells (Buchholz et al., 1996). For
Lkb1, two independent strategies were used to target exons 2 through 7 for
ablation (Figure 6, panels A and F). All target constructs were linearized and
electroporated into ES cells. Individual ES cell clones (3700 for Mat1, and 3800 for
Lkb1) were isolated, expanded, frozen and DNAs extracted from these cells were
screened for homologous recombination by Southern blotting. ES cell clones were
confirmed to be correctly targeted (13 for Mat1, 5 for Lkb1), and cells from
individual lines were subsequently injected into C57/BL6 blastocysts which were
then surgically implanted into the uterine horns of pseudopregnant females.
Chimeric animals were identified by coat color and several males for each strategy
were subsequently identified to be transmitting the targeted allele through the
germline by Southern blotting and PCR genotyping. Experimental and control mice
were maintained on several heterogeneous genetic backgrounds
PCR Genotyping (I, II, III, IV)
Tail clips from ear-marked animals (3-4 weeks old) were incubated overnight at
55oC in 200 µl of buffer containing 50 mM KCl, 0.1mM Tris pH 8.3, 0.2 mM MgCl2,
0.1% gelatin, 0.45% IPEGAL CA-630, 0.45% Tween 20 and 1 mg/ml proteinase K.
The following day the proteinase K was inactivated by heating the tubes for 100o C
for 10 minutes followed by PCR using 1 µl of tail prep as a template. PCR reactions
were performed in a thermocycler by heating the reaction at 95o C for  minutes
followed by 35 cycles of 95oC for 50 seconds, 58oC for 50 seconds, 72oC for 50
seconds. Reaction products were run on 1.5% agarose gels.
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Figure 5: Generation of a Mat1 loxP conditional targeting vector.
The endogenous Mat1 locus spanning the targeted exon (black tab) is schematized at the top of the
figure. Cloning steps in the construction of the vector are indicated with arrows. Restriction sites are
abbreviated as follows: B, BamH1; S, Sal1; C, Cla1; H, HindIII; N, Not1; K, Kpn1; ScI, SacI; ScII,
SacII; and Xb, Xba1. Introduced sites are in red. The parental pDelboy vector was constructed by
D.J. Rossi and is available upon request.
Protein Analysis (I, II, III, IV)
Protein lysates from whole tissue samples were made by dissecting tissues from
sacrificed animals and snap-freezing the samples in liquid nitrogen followed by
pulverization with a liquid nitrogen chilled tissue homogenizer. Lysates from tissue
culture were prepared directly from PBS washed tissue culture plates on ice. All
lysates were prepared in ELB lysis buffer and protein concentrations were
determined by spectrophotometry. For Western blotting analysis, samples were
separated on SDS-polyacrylamide gels, transferred onto nitrocellulose membranes,
and immunoblotted followed by detection with ECL reagents. Kinase assays were
performed according to standard protocols.
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Figure 6. Generation of Lkb1 mutant mice.
A Strategy 1 for disrupting exons 2-7 of the murine Lkb1. B Southern blotting with 5' probe. C
Southern blotting with a 3' probe. D PCR genotyping of targeted animals. E PCR genotyping of yolk
sac DNAs isolated from E9.5 conceptuses. F Strategy 2 for disrupting exons 2-7 of the murine Lkb1.
lox P sites are indicated with open triangles. G Southern blotting with 5' probe. H Southern blotting
with 3' probe. I PCR genotyping of targeted animals. J  PCR genotyping of yolk sac DNAs isolated
from E9.5 conceptuses. Neo, Neomycin selection cassette; TK, thymidine kinase selection cassette;
B, BamHI; H, HindIII; R1, EcoRI; ScI, SacI.
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Immunofluoresence and Immunohistochemistry (I, II, III, IV)
Immunofluoresence was performed variably depending upon the antibodies used.
Cell culture or freshly dissected tissue samples were fixed in either 3.5% PFA,
Ethanol or methanol followed by a permeabilization with either 0.5% Triton X-100 in
PBS or with cold methanol. Samples were blocked in 10% FCS in PBS. Primary
and secondary antibodies were left on the samples for varying amounts of time
depending on the experiment. DNA was visualized by staining with Hoechst 33342.
Each step was followed by 3 to 4 washes with PBS with a final rinse in water
before mounting. Samples on coverslips were mounted onto glass slides for
epifluorescence microscopy. Immunohistochemistry of paraffin embedded tissues
was performed according to standard protocols following epitope unmasking by
microwaving samples at full power for 5 minutes in 10 mM sodium citrate buffer.
Blastocyst Outgrowths (I)
Mat1 heterozygous animals were intercrossed and plugged females were
sacrificed 2.5 days post-coital. Morula stage embryos (16-32 cell) were then
flushed from the oviducts and maintained in culture for 48 h. Expanded blastocysts
were then transferred to micro-well plates seeded with coverslips and maintained in
culture for up to 7 days.
Microinjection (I)
Trophoblast giant cells from blastocyst outgrowths were microinjected with 25 ng/µl
of pEGFP-N2 (Clontech) and 0.1 mg/ml Texas Red dextran tracer dye. Cells were
injected for 0.5 seconds under 120 hPa pressure using an Eppendorf microinjector
and transjector and a Zeiss Axiovert microscope. After injection, cells were washed
twice with media, returned to the incubator and analyzed 24 h later by fluorescence
microscopy.
BrdU labeling (I, II)
For BrdU labeling of blastocysts and outgrowths, cells were cultured in the
presence of 10 µM BrdU for 16 and 46 hours, respectively. Cells were then fixed in
4% PFA, washed with PBS, and treated with 0.5N HCl for 30 minutes followed by
immunofluorescence. For labeling of sciatic nerves, experimental animals were
intraperitoneally injected once a day for 10 days with 50 µg/g body weight of BrdU
in 0.9% NaCl, 7 mM NaOH solution. On day 11 sciatic nerves were collected and
cryosectioned before immunodetection of BrdU.
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Transmission Electron Microscopy (II)
Sciatic nerves were fixed in 1% PFA, 0.5% glutaraldehyde for 2 hours, treated with
1% osmium tetroxide (OsO4), dehydrated in ethanol, and embedded in epoxy resin.
Ultra-thin sections (60-90 nm) were cut and stained with uranyl acetate and lead
citrate followed by transmission electron microscopy.
TUNEL labeling (III)
Terminal deoxytransferase-mediated deoxy-uridine nick end-labeling analysis was
performed using the In Situ Cell Death Detection Kit (Roche) according to
manufacturer’s instructions.
Whole-mount Immunostaining (III)
For whole-mount immunostainings, E8.5 or E9.5 embryos were fixed in 4%
paraformaldehyde, bleached for 5 hours in 5% H2O2-95% methanol, and blocked
overnight (4OC) in PBS containing 3% milk and 0.1% Triton X-100. After an
overnight (4OC) incubation with primary antibodies (PECAM-1, Pharmingen;
Smooth muscle actin, Sigma), the embryos were treated with peroxidase-
conjugated secondary antibodies, and developed in 3,3´
diaminobenzidinetetrahydrochloride (Sigma).
Whole-mount in situ Hybridization (III)
Embryos were fixed in 4% PFA, bleached in 7% H2O2/93% methanol, treated with
5 µg/ml proteinase K and post-fixed in 4% PFA/0.2% glutaraldehyde. Digoxygenin-
UTP-labeled anti-sense probes were hybridized overnight at 63OC followed by
RNaseA/RNaseT1 treatment and blocking in 10% goat serum. Signal was then
visualized using an alkaline phosphatase conjugated anti-digoxigenin antibody and
detection with BM purple.
VEGF Concentration Determination (III)
For the VEGF analysis, 25,000 MEFs from individual embryos at passage 3 were
plated on 24-well plates and cultured in normoxic (21% O2) or hypoxic (1% O2 )
conditions for 24 hours. Conditioned medium was removed and VEGF
concentration was analyzed by enzyme-linked immunosorbent assay (ELISA)
(R&D Systems).
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Histology (II, III, IV)
Tissues were fixed over night in 4% paraformaldehyde (PFA) followed by
dehydration through an ethanol/xylene series and embedded in paraffin. Samples
were sectioned at 7 µm and mounted on glass slides. Histological sections were
then deparaffinized, rehydrated and stained with hematoxylin eosin (HE), Herovici’s
stain or immunostained and analyzed by light microscopy.
In situ Hybridization (III, IV)
Hybridization was carried out using sense and anti-sense probes made by in vitro
transcription in the presence of 35S-UTP. In situ hybridizations were performed
essentially according to standard protocols (Wilkinson et al., 1990) with some
modifications (Luukko et al., 1996).
Laser Micro-dissection (IV)
PFA-fixed, paraffin embedded polyp and control tissues were sectioned at 3 µm
onto LPC-membrane coated glass slides (P.A.L.M. Mikrolaser Technologie) and
dissected using a Robot-Microbeam laser micro-dissector (P.A.L.M.).
Human Peutz Jeghers Syndrome Tumor Samples (IV)
Polyps from Peutz-Jeghers syndrome patients were surgically resected and fixed in
10% formalin. Histological sectioning and staining was done as described above
for murine tissue samples.
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RESULTS AND DISCUSSION
Targeted disruption of Mat1 Leads to Embryonic Lethality (I)
To study the function of Mat1 in vivo, sequences encoding most of the RING finger
domain of Mat1 were targeted for disruption in ES cells with the aim of generating a
null allele. Targeted ES cell clones were then used to generate chimeric animals,
several of which were subsequently found to transmit the targeted allele in the
germline. Western blot analysis on lysates from targeted ES cells using a Mat1
antibody revealed no evidence of truncated Mat1 proteins suggesting that the
targeted allele is a true null.
Mat1 heterozygous (Mat1+/-) intercrosses were set and analysis of F1 litters
indicated that while both Mat1+/+ and Mat1+/- animals were observed at expected
Mendelian frequencies, no homozygote null animals (M t1-/-) were obtained. This
result indicated that disruption of Mat1 leads to embryonic lethality. Analysis of
embryos at various stages of embryonic development indicated that the lethality
associated with Mat1 disruption occurred shortly after implantation yet before
gastrulation.
As the Mat1 homologue in S. cerevisiae (rig2/tfb3) is an essential gene (Faye et al.,
1997) it was therefore surprising that early mammalian embryogenesis would
proceed in a genetically Mat1 null background. We therefore examined whether
survival of Mat1-/- embryos to the implantation stage of development might be due
to maternally provided Mat1 by immunostaining pre-implantation embryos (at 8-
cell, 16-cell, and blastocyst stages) for Mat1 expression. We observed diminishing
Mat1 immunoreactivity in Mat1-/- embryos such that by the blastocyst stage, Mat1
signal was barely observable.
Taken together, these results indicate that disruption of murine Mat1 leads to peri-
implantation lethality and that the timing of the lethality likely reflects the depletion
of maternal Mat1 protein below threshold levels required to sustain an essential
function.
Mat1 is required for viability in mitotic but not post-mitotic embryonic
lineages (I)
To examine more directly the role of Mat1 in cell proliferation and differentiation we
followed the development of pre-implantation embryos derived from Mat1+/-
intercrosses in blastocyst outgrowth cultures. We found that while both Mat1+/- and
Mat1+/+ outgrowths established both mitotic inner cell mass (ICM) cells and post-
mitotic trophoblast giant cells, the Mat1-/- embryos only gave rise to post-mitotic
trophoblast giant cells. This result indicated that Mat1 was required for the viability
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of mitotic embryonic lineages but not post-mitotic embryonic lineages. Moreover,
these results allowed us to address the function of Mat1 beyond embryonic lethality
by taking advantage of the blastocyst outgrowth system as a means of generating
a population of Mat1-/- trophoblast giant cells for further analysis. It should be noted
that as Mat1+/- and Mat1+/+ outgrowths are phenocopies of each other and were
both used as controls in subsequent experiments, they are therefore collectively
referred to as Mat1wt.
Mat1 specifically regulates the steady state levels of Cdk7 and cyclin H (I)
As Mat1 has been implicated in stabilizing the Cdk7-cyclin H-Mat1 trimer (Devault
et al., 1995; Fisher et al., 1995; Tassan et al., 1995), we therefore wanted to
address whether or not the expression of Cdk7 and cyclin H was affected in Ma 1-/-
cells. We therefore immunostained outgrown trophoblast cells and found that
immunoreactivity of both Cdk7 and cyclin H was consistently diminished in the
Mat1-/- cells compared to control cells. In order to determine whether this result was
specific to Mat1 loss or instead a manifestation of a more general transcriptional
deregulation, we immunostained for expression of several additional proteins
including PCNA, p53, Cdk2, cyclin E, cyclin D1, Cdk6 and the large subunit of RNA
polymerase II. We found that the expression of all of these proteins was
comparable in both Mat1-/- and Mat1wt cells. These results indicate that the loss of
mammalian Mat1 does not globally deregulate transcription or translation and
suggest that Mat1 specifically regulates the steady state levels of Cdk7 and
cyclin H in vivo.
Mat1 modulates RNA polymerase II CTD phosphorylation (I)
As many studies have implicated the CTD of the large subunit of RNA polymerase
II as a physiological substrate of TFIIH kinase activity, we therefore wanted to
analyze the phosphorylation status of the CTD in Mat1-/- cells. This was
accomplished by immunofluorescence analysis utilizing monoclonal antibodies
recognizing specific phosphoepitopes of pol II (Thompson et al., 1989; Patturajan
et al., 1998). These experiments indicated that while total pol II expression was
unaffected by the loss of Mat1, phosphorylation at serine 2 (Ser-2) and serine 5
(Ser-5) of the heptapeptide repeat of the CTD was diminished in the Mat1-/- cells.
These results provide evidence that Mat1 modulates the phosphorylation of pol II i
vivo either by phosphorylating the CTD directly or by regulating the activity of other
CTD kinases.
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Transcription and translation of an exogenous construct in Mat1-/- cells (I)
In order to more directly assay the ability of Mat1-/- cells to engage in de novo
transcription and translation, an exogenous CMV promoter-driven green
fluorescent protein (GFP) expression plasmid was microinjected into outgrowth
trophoblast cells and assayed for GFP expression the following day. Regardless of
genotype, all microinjected cells exhibited strong expression of the GFP protein
indicating that Mat1-/- cells were comparable to control cells in their ability to
engage in de novo transcription and translation of the exogenous construct.
Mat1 is required for S phase entry in trophoblast giant cells (I)
We noted that the Mat1-/- trophoblast cells in our outgrowth experiments were
consistently smaller in size and stained less intensely for DNA than control cells.
As trophoblast giant cells normally undergo DNA synthesis by endoreduplication
(Barlow et al., 1972), our observations suggested that the Mat1-/- cells might be
defective in this process. In order to examine this possibility in detail, the DNA
content of outgrown cells was quantified by measuring fluorescence intensity of
DNA (Hoechst 33342) stained nuclei. This analysis revealed that the Mat1-/-
trophoblast cells had undergone markedly less DNA synthesis than had controls.
Blastocysts and outgrowths were then BrdU labeled to identify cells undergoing
DNA synthesis. We found that while both Mat1-/- and Mat1wt blastocysts showed no
difference in DNA synthesis only wild type trophoblasts were actively engaged in
DNA synthesis while the Mat1-/- outgrowths were arrested. These results indicated
that coincident with depletion of maternal Mat1 stores, Mat1-/- cells were unable to
enter S phase and were arrested in the endocycle thereby demonstrating an
essential role for Mat1 in endocycle progression. Combined with our data
demonstrating the transcriptional integrity of the Mat1-/- trophoblast cells, we
propose that the observed endocycle arrest may be due to defects in Cdk
activation.
Generation of Mat1 loxP conditional (flox) mice (II)
To study the function of Mat1 in a tissue specific manner in vivo, a vector designed
to conditionally disrupt Mat1 in a loxP/Cre-recombinase-dependent manner was
constructed and introduced into ES cells (Figure 5). Correctly targeted ES cell
clones were then used to generate mice bearing the conditionally targeted allele
(Mat1flox). The Mat1flox/flox mice were found to be aphenotypic indicating that the
conditional allele had no overt hypomorphic effects. The functionality of the Mat1flox
allele was then tested in vivo by crossing Mat1flox/flox mice to a PGK driven Cre-
deleter strain (Lallemand et al., 1998) resulting in the recombined allele being
observed in all offspring (Mat1+/-). To generate Mat1-/- cell populations, Mat1flox/-
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animals were crossed to Krox-20-Cre knock-in mice (KCN) in which the Cre
recombinase is expressed under the control of the endogenous Krox-20 promoter
(Voiculescu et al., 2000). The use of this system enabled us to target Mat1 for
tissue specific ablation in the mitotic cells of male germ lineage upon sexual
maturation, and in post-mitotic myelinating Schwann cells of the peripheral nervous
system (Topilko et al., 1994; Voiculescu et al., 2000).
Mat1 is required for the viability of mitotic germ cells (II)
Mat1 was targeted for ablation in the mitotic cells of the male germ lineage by
crossing Mat1flox/- animals with the Krox-20-Cre strain. In the seminiferous tubules
of the testis of mutant animals at 6 weeks post-natal, pycnotic germ cells were
readily observed. Moreover, an underrepresentation or absence of cells
corresponding to the different stages of spermatid differentiation was also noted.
These observations were indicative of spermatogonia and spermatocyte cell death
and suggested a requirement of Mat1 for germ lineage viability. This assertion was
confirmed by examination of the testis of mutant animals at 14 weeks post-natal,
which revealed that they were entirely devoid of all germ cells and their derivatives.
These results demonstrate that Mat1 is required to maintain the viability of the
mitotic germ cells.
Targeted disruption of Mat1 in myelinated Schwann cells (II)
Although myelinated Schwann cells are post-mitotic they are nonetheless highly
transcriptionally active particularly during the first month postnatal during which
time great quantities of transcripts encoding myelin structural components are
generated (Stahl et al., 1990). By disrupting Mat1 in the Schwann cells at the onset
of myelination we were therefore able to address the role of Mat1 in an active
transcriptional context unencumbered by the demands of cell cycle progression.
We found that the histology of Mat1-deficient myelinated Schwann cells was
comparable to controls through the first two months of age. Moreover, the Mat1-
deficient cells were found to express several myelination markers at wild type
levels. These data indicated that Mat1-deficient myelinated Schwann cells were
able to assume a differentiated mature myelinated phenotype suggesting that Mat1
was not required for the transcription underlying myelination.
At around three months of age however, the mutant animals began to exhibit a
variety of symptoms including gait abnormalities, ataxia and muscular atrophy in
the hind limbs suggestive of a neuromuscular neuropathy. Examination of sciatic
nerves from mutant animals before symptomatic onset revealed that they were
normal while animals beyond the age of symptomatic onset showed multiple signs
of disease pathology. These observations provided evidence that myelinated
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Schwann cells succumb to Mat1 loss at around three months post-natal resulting in
a severe demyelination of peripheral axons followed by remyelination.
Taken together, these results suggest that Mat1 may be involved in regulating a
subset of genes required for maintaining Schwann cell integrity rather than
mediating an essential function in RNA polymerase II transcriptional activity.
Remyelination by non-myelinated Schwann cells (II)
The extent of remyelination that we observed in the mutant sciatic nerve suggested
that a proliferative response might underlie the remyelination phenotype. To test
this possibility, in vivo BrdU labeling experiments were done with mutant and
control animals followed by double immunofluorescence labeling (BrdU and
Krox-20) on sciatic nerve sections to reveal proliferation in the Schwann lineage.
These results indicated that the remyelination in mutant sciatic nerves was
coincident with proliferation of the Schwann cell lineage.
The myelinated Schwann lineage of the peripheral nervous system has been
shown to have a great capacity for regeneration in response to injury and both
myelinated and non-myelinated Schwann cells have been implicated in the
remyelination process (Griffin et al., 1990; Messing et al., 1992; Stoll and Muller,
1999). As the insult leading to demyelination in our model is the result of the
genetically programmed death of the myelinated Schwann lineage, this suggests
that the non-myelinating Schwann cell pool must therefore underlie the
remyelination observed in our mutant animals.
Targeted disruption of Lkb1 Leads to Midgestation Embryonic Lethality (III)
To study the function of Lkb1 in vivo, sequences encoding exons 2-7 of the murine
Lkb1 gene were disrupted by homologous recombination in ES cells. Targeted ES
cell clones were then used to generate chimeric animals, which were subsequently
found to transmit the targeted allele in the germline. No live Lkb1 homozygote null
animals (Lkb1-/-) were recovered from Lkb1 heterozygous (Lkb1+/-) intercrosses
indicating that disruption of Lkb1 leads to embryonic lethality. Analysis of embryos
throughout embryonic development revealed that Lkb1-/- embryos beyond E8.5 had
multiple developmental abnormalities including a failure of the embryo to turn, a
defect in neural tube closure, and a hypoplastic or absent first branchial arch. No
viable embryos were recovered past E11.0, indicating that Lkb1 is essential for
embryonic development.
The integrity of various developmental lineages in E8.5 and E9.5 Lkb1-/- embryos
was examined by whole-mount i  situ hybridization. The expression of the
mesodermal marker brachyury (Wilkinson et al., 1990) showed that although the
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notochord developed along the full length of the anterior/posterior axis in the
mutant embryos, it was misaligned and contorted. This was accompanied by
defective somitogenesis, which resulted in dysmorphic protrusive somites, which
failed to express engrailed 1 (Joyner and Martin, 1987) at E9.5. No pronounced
changes in the expression of Wnt3A, Fgf8 or Krox-20 were noted, suggesting
normal development of the mesoderm of the tail bud, forebrain and primitive streak,
and normal segmentation of the hindbrain.
Embryonic and Extraembryonic Vascular Defects in Lkb1-/- Mice (III)
It was noted that Lkb1-/- embryos at E9.25 had a translucent appearance,
suggesting the possibility of vascular defects. We therefore immunostained E8.5
and E9.5 embryos with an antibody against platelet endothelial cell adhesion
molecule-1 (PECAM-1) to visualize the endothelial cells of the embryonic
vasculature. These experiments revealed a number of vascular defects in the
mutant embryos including defective development of the aorta which was thin and
discontinuous and whose intersomitic branches terminated prematurely in the
mesenchyme. Abnormalities were also observed in the vascular smooth muscle
cells as revealed by immunostaining with and antibody against smooth muscle
actin suggesting that defects in vascular support cell development may contribute
to the vascular defects observed in the Lkb1-/- embryos.
In addition to embryonic vascular defects, we also noted defects in the
extraembryonic vasculature as the yolk sacs of mutant E9.5 conceptuses failed to
develop large vitelline vessels or an extensive capillary network. In contrast to
controls, the mutant yolk sac developed only rudimentary vessels, which were
often congested by pools of nucleated embryonic blood cells. The vitelline artery
was completely atretic in Lkb1-/- yolk sacs, effectively disconnecting the embryo
from the yolk sac (vitelline) circulation. We also observed that the placentas of
mutants at E9.5 were small and hemorrhagic. Although chorio-allantoic fusion was
noted in mutant conceptuses, invasion of embryonic blood vessels into the
placenta did not occur. In situ hybridization with probes for the VEGF receptors flk-
1 (Yamaguchi et al., 1993) and flt-1 (Dumont et al., 1995) which delineate migrating
and maturing embryonic vessels in the placenta (respectively) confirmed that the
fetal allantoic blood vessels did not migrate into the placenta. As a consequence, a
mature labyrinth layer did not develop in the mutant conceptuses.
Taken together, these results suggest that the Lkb1-/- embryos likely die at
midgestation due to the inability of the embryonic and extraembryonic vasculature
to develop properly in the absence of Lkb1.
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Deregulation of VEGF in Lkb1-/- tissues and cultured cells (III)
As vascular endothelial growth factor (VEGF) is known to be critical for embryonic
vascular development (Carmeliet et al., 1996; Ferrara et al., 1996), we therefore
did in situ hybridization experiments on mutant and control conceptuses with a
probe for VEGF. We found that expression of VEGF mRNA was markedly
diminished in the trophoblast giant cells of the mutant placenta, while the Lkb1-/-
embryos expressed elevated levels of VEGF. These results suggested that VEGF
was deregulated in both the embryonic and extraembryonic compartments of
mutant conceptuses.
To investigate whether Lkb1 directly regulated VEGF expression in cultured cells,
we isolated primary mouse embryonic fibroblasts (MEFs) from mutant and control
embryos and assayed for expression of VEGF. This analysis revealed that
expression of VEGF was significantly elevated in Lkb1-/- MEF cultures under both
stimulated (hypoxia) and non-stimulated conditions. These results indicated that
loss of Lkb1 leads to increased basal and induced expression of VEGF in
fibroblasts. Moreover, these results suggest a rationale for the increased risk of
cancer incidence associated with Peutz-Jeghers syndrome (Giardiello et al., 1987)
by demonstrating that loss of Lkb1 can confer an increased angiogenic potential in
certain cell types through up-regulation of VEGF.
Lkb1 functions as is a tumor suppressor in mice (IV)
Inactivating germline mutations of LKB1 lead to Peutz-Jeghers syndrome (PJS)
(Hemminki et al., 1998; Jenne et al., 1998). As Lkb1 heterozygous mice represent
the genetic equivalent of human Peutz-Jeghers patients, we therefore wanted to
examine whether Lkb1+/- mice were prone to a disease spectrum similar to that
found in PJS patients. To this end, cohorts of Lkb1+/- and control Lkb1+/+ mice were
established and monitored. We found that the Lkb1+/- mice had markedly reduced
life spans with ~ 80% dying by 16 months of age. It was noted that beyond the age
of 7 months, many of the Lkb1+/- mice presented grossly distended abdomens
suggesting gastrointestinal obstruction. At necropsy, macroscopic gastrointestinal
polyps were identified in 100% of the Lkb1+/- animals over 6 months of age with up
to 40 polyps scored in individual animals. The vast majority of the polyps were
localized to the glandular stomach. Moreover, very large pyloric polyps (20-30 mm
in diameter representing up to 25% of the total weight of the animal) were often
found protruding into the duodenum thereby rendering it grossly distended and
obstructed. Based on these observations, the high mortality associated with Lkb1
heterozygosity was likely due to gastrointestinal occlusion. Taken together, these
results indicate that Lkb1 functions as a suppressor of polyposis in mice.
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Polyposis in Lkb1+/- mice models Peutz-Jeghers syndrome (IV)
Histological examination of polyps from Lkb1+/- animals revealed that all were
hamartomas with well-differentiated glandular epithelium and normal lamina
propria. Strikingly, all polyps had an extensive, well-developed smooth muscle
component, which provided a latticed framework between pockets of glandular
epithelia. Histological comparison of polyps derived from Lkb1+/- mice to polyps
resected from human PJS patients revealed a striking similarity. Particularly, the
histology of the smooth muscle component, the most widely used criteria for
establishing diagnosis of PJS, was indistinguishable from the human polyps. It
should be noted however that while the murine Lkb1+/- polyps were found to be
predominantly gastric, polyps in PJS patients are found more evenly distributed
along the full length of the digestive tract with the highest frequency in the small
intestine (Utsunomiya et al., 1975).
In addition to the characteristic hamartomas that develop in Peutz-Jeghers
patients, PJS is also a cancer predisposition syndrome with patients exhibiting an
increased risk of developing cancers of both gastrointestinal and extraintestinal
origin in later life (Giardiello et al., 1987; Boardman et al., 1998). We however
found no evidence of an increased cancer incidence in Lkb1+/- mice compared to
control animals although we were unable to establish whether this held true in older
Lkb1+/- mice due to the compromised longevity of Lkb1+/- mice resulting from the
polyposis phenotype. Unlike human PJS patients, abnormal pigmentation of the
oral mucosa in Lkb1+/- mice was not observed.
Taken together, these results indicate that while Lkb1+/- mice model PJS polyposis,
the phenotype of these animals does not recapitulate all of the clinical aspects of
Peutz-Jeghers syndrome.
No evidence for genetic or epigenetic inactivation of Lkb1 in
Lkb1+/--associated polyps (IV)
Establishing that a gene functions as a tumor suppressor has traditionally relied on
the demonstration that both alleles of the putative tumor suppressor are inactivated
in order to promote tumorigenesis (Knudson, 1971). Studies addressing this issue
in human PJS polyposis have yielded inconsistent results with some groups
reporting that loss of heterozygosity (LOH) of LKB1 often accompanies polyp
formation (Gruber et al., 1998; Hemminki et al., 1998; Miyaki et al., 2000), while
others have reported that biallelic inactivation of LKB1 may be more rare (Wang et
al., 1999b; Entius et al., 2001). Thus, the question of whether or not LOH of LKB1
is an obligate initiating event in human PJS polyposis has remained unresolved. To
address this issue in our murine model, DNAs extracted directly from polyps or
from laser micro-dissected polyp samples (to isolate exclusively epithelial or
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stromal cell DNAs) were genotyped for wild type and mutant alleles. This analysis
indicated that both alleles were comparably amplified in all tumors analyzed.
Moreover, when the copy number of the wild type allele was assayed from polyp
and control DNAs by real-time PCR we found no statistical difference in the copy
number of the wild type allele in the polyps compared to controls.
It has been suggested that transcriptional silencing by promoter hypermethylation
may be an alternative mechanism by which LKB1 can be inactivated in PJS
patients that do not possess identifiable genetic second hits (Esteller et al., 2000).
In order to examine whether epigenetic inactivation might lead to biallelic
inactivation of Lkb1 in murine Lkb1+/- polyposis, we assayed for Lkb1 mRNA
expression by in situ hybridization in a number of polyps. This analysis
demonstrated that Lkb1 mRNA levels were maintained throughout the entirety of all
polyps examined at levels comparable to those observed in the adjacent
unaffected gastric epithelia and that Lkb1 was expression was retained in both the
stromal and epithelial cells of the polyp.
Taken together these results indicated that neither LOH of the wild type Lkb1 locus,
or epigenetic silencing of Lkb1 transcription were features of either of the major
cellular components comprising the polyps.
Haploinsufficiency of Lkb1 in polyposis of Lkb1+/- mice (IV)
Having found no evidence for biallelic inactivation of Lkb1 in the polyps of Lkb1+/-
animals, we speculated that haploinsufficiency of Lkb1 might underlie the
development of murine polyposis. This idea is not without precedent as a number
of tumor suppressor genes have recently been demonstrated to be
haploinsufficient for tumor suppression (Fero et al., 1998; Venkatachalam et al.,
1998; Wetmore t al., 2000; Inoue t al., 2001).
In order to explore this possibility, Lkb1 protein levels and activity were examined
from Lkb1+/+ and Lkb1+/- mouse embryonic fibroblasts. These results indicated that
Lkb1 protein expression was significantly reduced in Lkb1+/- cells compared to
Lkb1+/+ cells and that the reduced expression resulted in a similar decrease in Lkb1
kinase activity.
We then assayed for Lkb1 expression and activity from whole tissue lysates
prepared from multiple, independently isolated polyps, adjacent unaffected
stomachs, and stomachs from Lkb1+/+ animals. Similar to what had been observed
in MEFs, Lkb1 protein levels and activity in the unaffected stomachs of Lkb1+/-
animals were found to be lower than in wild type stomachs. Moreover, we found
that Lkb1 levels and activity in the polyps were comparable to those in adjacent
unaffected stomach lysates.
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Taken together, these data argue that murine Lkb1 is functionally haploinsufficient
for tumor suppression by providing molecular evidence that Lkb1 heterozygosity
leads to a reduction in Lkb1 expression and activity that is sufficient to mediate
polyposis in Lkb1+/- animals in the absence of biallelic inactivation.
Induction of cyclooxygenase-2 in murine and PJS polyps (IV)
Cyclooxygenase-2 (COX-2) has been demonstrated to promote gastrointestinal
tumorigenesis in a number of human and murine systems (Gupta and DuBois,
2001). Although COX-2 expression has frequently been shown to be upregulated in
gastrointestinal tumorigenesis in both mice (Williams et al., 1996) and in humans
(Eberhart et al., 1994; van Rees and Ristimäki, 2001), it has not been examined in
Peutz-Jeghers syndrome polyposis. We therefore assayed for expression of COX-
2 in polyp and stomach lysates to establish whether induction of COX-2 might be a
feature of murine Lkb1+/- polyposis. We found that expression of COX-2 was highly
upregulated in majority (75%) of the polyps examined.
COX-2 expression is known to be regulated by several signal transduction
pathways including those mediated by p38 MAP kinase, Akt/PKB, JNK kinases,
and Erk1/2 kinases. Analysis of activated mediators of these pathways in murine
Lkb1+/- polyposis revealed that only the Erk1/2 kinases were activated suggesting
that the Ras/Raf-1/MEK/ERK signal transduction pathway is likely to mediate COX-
2 induction in murine Lkb1+/- polyposis.
In order to investigate whether the induction of COX-2 that we observed in Lkb1+/-
murine polyps was also a feature of the polyposis associated with PJS patients, a
large number of human polyps (23 polyps from 5 PJS patients) were assayed for
COX-2 expression by immunohistochemistry. Elevated COX-2 expression was
observed in 70% (16/23) of the polyps examined. In all the samples, COX-2
immunoreactivity localized to the cytoplasm of the epithelial cells while the
surrounding stroma was negative apart from restricted sporadic staining. These
results indicate that upregulation of COX-2 expression is a common feature of PJS
polyposis.
Inhibition of cyclooxygenase enzymes with non-steroidal anti-inflammatory drugs
has proven effective in repressing gastrointestinal tumorigenesis (Thun et al., 1991;
Giardiello et al., 1993) In particular, COX-2 has emerged as the central target of
these therapies as shown by clinical trials utilizing selective COX-2 inhibitors
(Steinbach et al., 2000). Our finding that COX-2 expression is upregulated in a
significant percentage of human PJS polyps suggests that COX-2 inhibitors might
be useful in providing a first therapeutic approach in reducing the tumor burden and
need for surgery in Peutz-Jeghers patients.
                    Functional Analysis of Cell Cycle Regulators Lkb1 and Mat1 in Genetically Engineered Mice
45
CONCLUDING REMARKS AND FUTURE DIRECTIONS
The control of cell cycle progression is regulated in a myriad of different ways both
during embryonic development as well as in the adult. Cell cycle regulatory
molecules exert their effects through both autonomous and non-autonomous
mechanisms to promote or inhibit cell division. The tenuous balance in maintaining
control of the cell cycle is illustrated by the consequences that deregulation of key
cell cycle regulators impart on the organism – such as cancer development or
defective embryogenesis. However, it is precisely through the study of such
‘mutants’ that insight is gained into the underlying molecular biology of normal
growth and development as well as in disease initiation and progression.
Accordingly, mutational analysis has become the principal tool of the
developmental biologist and the cancer biologist alike.
The past 15 years has seen the emergence of gene targeting technologies that
have allowed for the generation of animals with specific alterations in the genome.
These technologies rely on the property of mouse embryonic stem (ES) cells to
remain pluripotent even after rigorous manipulation in v tro. ES cells can thus be
genetically modified at any locus in culture followed by returning these cells to the
embryo where they maintain the developmental capacity to contribute to any
lineage. Phenotypic analysis of targeted animals has proven a powerful tool in
gaining insight into the function of hundreds of genes in vivo. The first generation of
targeted animals was almost exclusively engineered to harbour loss of function,
null mutations (knockouts). The limitations of this approach soon became apparent,
particularly in cases in which the gene product of a targeted locus is essential for
early embryonic development. The second generation of targeted strategies
however found a way around these limitations with the use of site-specific
recombination systems to facilitate the control of the engineered mutation both
temporally (at specified times of embryonic development or in the adult) and
spatially (in specified tissues or cell types).
In the work presented in this dissertation, my colleagues and I have taken
advantage of the recent advances in genetic engineering and applied these
technologies to study the function of two key regulators of cell proliferation, Mat1
and Lkb1. This work has provided valuable insight into the function of these two
molecules in vivo, in addition to opening many doors to future experimentation.
Our work with Mat1 has demonstrated a requirement of Mat1 in both mitotic
embryonic and adult lineages. As Mat1 has been suggested to be a mediator of
cell cycle progression as a component of the Cdk-activating enzyme (CAK), it is
possible that the requirement that we see for Mat1 in mitotic lineages primarily
reflects a defect in Cdk-activation. This supposition is supported by our findings
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that Mat1-deficieny results in a cell cycle arrest of endocycling trophoblast giant
cells. Interestingly, this issue has a great opportunity of being experimentally
addressed by manipulating the systems we have generated in this current study.
Experimental design could involve taking loxP conditional Mat1 cells into culture,
introducing the Cre recombinase to these cells (by retrovirus or adenovirus
mediated transfer for example) and then examining the molecular biology of the
cell cycle machinery for evidence of defective Cdk-activation.
Unexpectedly, our work with Mat1-deficient trophoblast giant cells and myelinating
Schwann cells has provided evidence that mammalian Mat1 – and indeed TFIIH
kinase – is not an absolute regulator of RNA polymerase II mediated transcription
as had been previously suggested for TFIIH kinase homologues in yeast (Valay et
al., 1995; Valay et al., 1996; Faye et al., 1997; Holstege t al., 1998). Our results
suggest that either differences in experimental design account for this incongruity,
or that hitherto unexplored differences exist in the basal transcriptional apparatus
of yeast and mammals. Again, the systems we have generated could be
manipulated to address these issues. For example, gene chip technology for
analyzing genome wide changes in transcription profile could be utilized in
conjunction with Mat1-deficient tissues or cultured cells to address which
transcripts exhibit differential expression in the absence of Mat1.
Our work with Lkb1 has demonstrated a requirement for Lkb1 in murine embryonic
development, which we linked to severe defects in vascular development. The
vascular defects that we noted were coupled to a tissue specific deregulation of the
VEGF, a key regulator of angiogenesis. A link between Lkb1 and VEGF was
confirmed in culture with the discovery that Lkb1-deficient cells expressed
markedly elevated levels of VEGF. These results establish that Lkb1-deficiency
has the ability to confer an increased angiogenic potential on certain cell types.
These findings have obvious implications for the tumorigenic phenotypes of PJS
since the neovascularization of tumors serves both to satisfy the metabolic needs
of the tumor cells, as well as providing a possible route for metastasis (Folkman,
1995).
Our results demonstrating that mice heterozygous for a targeted inactivating allele
of Lkb1 develop a polyposis that models PJS provides compelling experimental
evidence of the primary role of LKB1 in the development of PJS. We were able to
show that, contrary to expectations, biallelic inactivation of Lkb1 did not accompany
tumorigenesis but rather that haploinsufficiency of Lkb1 was sufficient to mediate
the disease. These findings strongly suggest that PJS polyposis is also likely to be
mediated by haploinsufficiency of LKB1.
We have also discovered that, much like gastrointestinal adenoma and
adenocarcinoma development, both murine and PJS polyposis are associated with
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induction of Cyclooxygenase-2. This finding has significant clinical implications by
identifying COX-2 as the first potential target for chemoprevention in PJS
polyposis. To test the utility of such therapy, we have initiated experiments
administering the COX-2 inhibitor celecoxib to Lkb1+/- mice as a first step in
determining whether such treatment will be effective in lowering the tumor burden
in PJS patients. We have also undertaken steps towards initiating clinical trials to
test the efficacy of COX-2 inhibition in the reduction of PJS tumor burden.
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